Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis - PubMed (original) (raw)
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis
Rohit Mehra et al. Cancer Res. 2005.
Abstract
GATA binding protein 3 (GATA3) is a transcriptional activator highly expressed by the luminal epithelial cells in the breast. Here we did a meta-analysis of the available breast cancer cDNA data sets on a cohort of 305 patients and found that GATA3 was one of the top genes with low expression in invasive carcinomas with poor clinical outcome. To validate its prognostic utility, we did a tissue microarray analysis on a cohort of 139 consecutive invasive carcinomas (n = 417 tissue samples) immunostained with a monoclonal antibody against GATA3. Low GATA3 expression was associated with higher histologic grade (P < 0.001), positive nodes (P = 0.002), larger tumor size (P = 0.03), negative estrogen receptor and progesterone receptor (P < 0.001 for both), and HER2-neu overexpression (P = 0.03). Patients whose tumors expressed low GATA3 had significantly shorter overall and disease-free survival when compared with those whose tumors had high GATA3 levels. The hazard ratio of metastasis or recurrence according to the GATA3 status was 0.31 (95% confidence interval, 0.13-0.74; P = 0.009). Cox multivariate analysis showed that GATA3 had independent prognostic significance above and beyond conventional variables. Our data suggest that immunohistochemical analysis of GATA3 may be the basis for a new clinically applicable test to predict tumor recurrence early in the progression of breast cancer.
Similar articles
- LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA. Saha B, et al. Anticancer Res. 2004 Jul-Aug;24(4):2391-400. Anticancer Res. 2004. PMID: 15330189 - GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D, Cheang M, Nielsen T. Voduc D, et al. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73. doi: 10.1158/1055-9965.EPI-06-1090. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18268121 - FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. Badve S, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21. doi: 10.1158/1078-0432.CCR-07-0122. Clin Cancer Res. 2007. PMID: 17671124 - Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
Badve S, Nakshatri H. Badve S, et al. J Clin Pathol. 2009 Jan;62(1):6-12. doi: 10.1136/jcp.2008.059899. Epub 2008 Sep 15. J Clin Pathol. 2009. PMID: 18794199 Review. - Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis.
Guo Y, Yu P, Liu Z, Maimaiti Y, Chen C, Zhang Y, Yin X, Wang S, Liu C, Huang T. Guo Y, et al. PLoS One. 2017 Apr 10;12(4):e0174843. doi: 10.1371/journal.pone.0174843. eCollection 2017. PLoS One. 2017. PMID: 28394898 Free PMC article. Review.
Cited by
- KDM4B is a master regulator of the estrogen receptor signalling cascade.
Gaughan L, Stockley J, Coffey K, O'Neill D, Jones DL, Wade M, Wright J, Moore M, Tse S, Rogerson L, Robson CN. Gaughan L, et al. Nucleic Acids Res. 2013 Aug;41(14):6892-904. doi: 10.1093/nar/gkt469. Epub 2013 May 30. Nucleic Acids Res. 2013. PMID: 23723241 Free PMC article. - Decoding the basis of histological variation in human cancer.
Fujii M, Sekine S, Sato T. Fujii M, et al. Nat Rev Cancer. 2024 Feb;24(2):141-158. doi: 10.1038/s41568-023-00648-5. Epub 2023 Dec 22. Nat Rev Cancer. 2024. PMID: 38135758 Review. - Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer.
Decker JT, Kandagatla P, Wan L, Bernstein R, Ma JA, Shea LD, Jeruss JS. Decker JT, et al. Cancer Biol Ther. 2020 Nov 1;21(11):994-1004. doi: 10.1080/15384047.2020.1818518. Epub 2020 Oct 14. Cancer Biol Ther. 2020. PMID: 33054513 Free PMC article. - KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y, Wu H. Lan T, et al. Mol Cancer. 2019 Dec 19;18(1):186. doi: 10.1186/s12943-019-1106-z. Mol Cancer. 2019. PMID: 31856849 Free PMC article. - Gata-3 and mammary cell fate.
Naylor MJ, Ormandy CJ. Naylor MJ, et al. Breast Cancer Res. 2007;9(2):302. doi: 10.1186/bcr1661. Breast Cancer Res. 2007. PMID: 17381824 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous